tradingkey.logo

Precipio Inc

PRPO
查看详细走势图
20.060USD
-0.310-1.52%
收盘 02/06, 16:00美东报价延迟15分钟
35.02M总市值
亏损市盈率 TTM

Precipio Inc

20.060
-0.310-1.52%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.52%

5天

-18.26%

1月

-13.12%

6月

+44.32%

今年开始到现在

-12.71%

1年

+201.46%

查看详细走势图

TradingKey Precipio Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Precipio Inc当前公司基本面数据相对稳定,最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理,在医疗设备与耗材行业排名145/205位。机构持股占比非常高,中期看,股价处于平稳状态。近一个月,市场表现非常差,但技术面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Precipio Inc评分

相关信息

行业排名
145 / 205
全市场排名
471 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Precipio Inc亮点

亮点风险
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
业绩高增长
公司营业收入稳步增长,连续3年增长96.90%
业绩增长期
公司处于发展阶段,最新年度总收入18.53M美元
估值低估
公司最新PE估值-24.90,处于3年历史低位
机构加仓
最新机构持股342.90K股,环比增加20.32%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值25.56K
活跃度降低
近期活跃度降低,过去20天平均换手率0.14

分析师目标

根据 0 位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Precipio Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Precipio Inc简介

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
公司代码PRPO
公司Precipio Inc
CEODanieli (Ilan S)
网址https://www.precipiodx.com/
KeyAI